TOP TEN perturbations for 39995_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39995_s_at
Selected probe(set): 219077_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39995_s_at (219077_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):-4.595752Number of Samples:2 / 3
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Relative Expression (log2-ratio):-4.1604204Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Relative Expression (log2-ratio):-4.1045933Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). |
cisplatin study 4 (20uM) / vehicle (PBS) treated HepG2 sample
Relative Expression (log2-ratio):-3.761496Number of Samples:3 / 12
| Experimental | cisplatin study 4 (20uM) |
| HepG2 cells treated with compound: cisplatin (20uM; CAS no.:15663-27-1) for 24 hours. Cisplatin is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 72 hours. ATC code: | |
| Control | vehicle (PBS) treated HepG2 sample |
| HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours. |
ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):3.758604Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
cyclophosphamide study 6 (8155 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample
Relative Expression (log2-ratio):-3.7332325Number of Samples:3 / 8
| Experimental | cyclophosphamide study 6 (8155 uM; hES-Heps) |
| hES-Heps cells exposed to 8155 uM cyclophosphamide (dissolved in 0.5% v/v DMSO) for 72 hours. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code: | |
| Control | vehicle (DMSO) treated hES-Heps cell sample |
| hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation. |
cisplatin study 7 (48h) / vehicle (PBS) treated HepG2 cell sample
Relative Expression (log2-ratio):-3.706049Number of Samples:3 / 9
| Experimental | cisplatin study 7 (48h) |
| HepG2 cells exposed to 20μM cisplatin in PBS solvent for 48 hours. ATC code: | |
| Control | vehicle (PBS) treated HepG2 cell sample |
| HepG2 cells exposed to 0.5% PBS solvent for 48 hours. |
polyamide study 1 (match) / mifepristone study 4
Relative Expression (log2-ratio):-3.6913986Number of Samples:3 / 3
| Experimental | polyamide study 1 (match) |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. | |
| Control | mifepristone study 4 |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and 3µM of the glucocorticoid receptor antagonist mifepristone. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code: |
polyamide study 1 (mismatch) / mifepristone study 4
Relative Expression (log2-ratio):-3.6214275Number of Samples:3 / 3
| Experimental | polyamide study 1 (mismatch) |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a mismatched synthetic DNA-binding polyamide (normally targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. | |
| Control | mifepristone study 4 |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and 3µM of the glucocorticoid receptor antagonist mifepristone. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code: |
polyamide study 1 (match) / vehicle (medium) treated A549 cell sample
Relative Expression (log2-ratio):-3.594263Number of Samples:3 / 3
| Experimental | polyamide study 1 (match) |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. | |
| Control | vehicle (medium) treated A549 cell sample |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. Samples were taken after additional 56 hours. |